BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
BioLineRx (NASDAQ: BLRX, TASE: BLRX) will release its Q3 2026 financial results on November 23, 2026, before U.S. market open. A conference call at 8:30 a.m. EST will feature CEO Philip Serlin. The company is a clinical-stage biopharmaceutical firm focused on oncology and rare diseases, with lead asset GLIX1 in Phase 1/2a trials.



